2017

Tofacitinib in UC

Phase 2 trial Risankizumab in Crohn’s disease

Topical tacrolimus in UC proctitis

PF-00547659 in UC

Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials

Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD

ADA vs AZA in postop recurrence in CD

Infliximab or surgery in ileal CD

Efficacy and Safety of Oral Budesonide in Patients with Active Crohn’s Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study

Multidonor intensive fecal microbiota transplantation in UC